Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

Antineoplastic Agents / therapeutic use Carcinoma, Hepatocellular / drug therapy Female Humans Italy Liver Neoplasms / drug therapy Male Middle Aged Neoplasm Staging Prognosis Proportional Hazards Models Prospective Studies Retrospective Studies Risk Assessment / methods Severity of Illness Index Sorafenib / therapeutic use Treatment Outcome

Cohort study Hepatocellular carcinoma Prognosis Sorafenib Survival

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

ISSN: 1878-3562

Titre abrégé: Dig Liver Dis

Pays: Netherlands

ID NLM: 100958385

Informations de publication

Date de publication:
Aug 2021

Historique:

received: 09 09 2020

revised: 30 11 2020

accepted: 02 12 2020

pubmed: 24 12 2020

medline: 3 2 2022

entrez: 23 12 2020

Statut: ppublish

Résumé

Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p<0.001) at univariate analysis, except the Albumin-Bilirubin score. The Italian Liver Cancer score (CLIP) yielded the highest accuracy (C-index 0.604, AIC 9898), followed by the ITA.LI.CA. prognostic score (C-index 0.599, AIC 9915). The CLIP score had the highest accuracy in predicting the overall survival of HCC patients treated with Sorafenib, although its performance remained poor. Further studies are needed to refine the current ability to predict the outcome of HCC patients undergoing Sorafenib.

Sections du résumé

BACKGROUND BACKGROUND

Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients.

AIMS OBJECTIVE

To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort.

METHODS METHODS

The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC).

RESULTS RESULTS

Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p<0.001) at univariate analysis, except the Albumin-Bilirubin score. The Italian Liver Cancer score (CLIP) yielded the highest accuracy (C-index 0.604, AIC 9898), followed by the ITA.LI.CA. prognostic score (C-index 0.599, AIC 9915).

CONCLUSIONS CONCLUSIONS

The CLIP score had the highest accuracy in predicting the overall survival of HCC patients treated with Sorafenib, although its performance remained poor. Further studies are needed to refine the current ability to predict the outcome of HCC patients undergoing Sorafenib.

Identifiants

DOI: 10.1016/j.dld.2020.12.001 PMID: 33353858

pubmed: 33353858

pii: S1590-8658(20)31059-8

doi: 10.1016/j.dld.2020.12.001

pii:

doi:

Substances chimiques

Antineoplastic Agents 0

Sorafenib 9ZOQ3TZI87

Types de publication

Comparative Study Evaluation Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

Pagination

1011-1019

Commentaires et corrections

Type : CommentIn

Informations de copyright

Déclaration de conflit d'intérêts

Declaration of Competing Interest None declared.